{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:19Z","timestamp":1794047419376,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281315","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T03:15:10Z","timestamp":1663816510000},"page":"261-266","source":"Crossref","is-referenced-by-count":21,"title":["Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality"],"prefix":"10.3324","volume":"108","author":[{"given":"Ioannis","family":"Karampinis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Koett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Gaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Thomas","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Goertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Werner","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Thomas","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"43412","doi-asserted-by":"crossref","unstructured":"Mulder FI, Horvath-Puho E, van Es N. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021; 137(14):1959-1969.","DOI":"10.1182\/blood.2020007338"},{"key":"43413","doi-asserted-by":"crossref","unstructured":"Wang TF, Li A, Garcia D. Managing thrombosis in cancer patients. Res Pract Thromb Haemost. 2018; 2(3):429-438.","DOI":"10.1002\/rth2.12102"},{"key":"43414","doi-asserted-by":"crossref","unstructured":"Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treat Rev. 2022; 102:102322.","DOI":"10.1016\/j.ctrv.2021.102322"},{"key":"43415","doi-asserted-by":"crossref","unstructured":"Bauer AT, Suckau J, Frank K. Von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015; 125(20):3153-3163.","DOI":"10.1182\/blood-2014-08-595686"},{"key":"43416","doi-asserted-by":"crossref","unstructured":"Goertz L, Schneider SW, Desch A. Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget. 2016; 7(42):68527-68545.","DOI":"10.18632\/oncotarget.11832"},{"key":"43417","doi-asserted-by":"crossref","unstructured":"Bohm M, Gerlach R, Beecken WD. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb Res. 2003; 111(1-2):33-37.","DOI":"10.1016\/j.thromres.2003.08.018"},{"key":"43418","doi-asserted-by":"crossref","unstructured":"Koo BH, Oh D, Chung SY. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb Res. 2002; 105(6):471-476.","DOI":"10.1016\/S0049-3848(02)00053-1"},{"key":"43419","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Karimi M, Mosalaei A, Canciani MT, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica. 2003; 88(4):454-458.","DOI":"10.1111\/j.1538-7836.2003.tb05764.x"},{"key":"43420","unstructured":"Martini F, Ferroni P, Guadagni F. Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res. 2005; 25(1B):403-407."},{"key":"43421","doi-asserted-by":"crossref","unstructured":"Obermeier HL, Riedl J, Ay C. The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost. 2019; 3(3):503-514.","DOI":"10.1002\/rth2.12197"},{"key":"43422","doi-asserted-by":"crossref","unstructured":"Guo R, Yang J, Liu X, Wu J, Chen Y. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer. J Clin Lab Anal. 2018; 32(1):e22219.","DOI":"10.1002\/jcla.22219"},{"key":"43423","doi-asserted-by":"crossref","unstructured":"Takaya H, Namisaki T, Kitade M. VWF\/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019; 19(1):167.","DOI":"10.1186\/s12876-019-1082-1"},{"key":"43424","doi-asserted-by":"crossref","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4):458-464.","DOI":"10.1001\/archinte.166.4.458"},{"key":"43425","doi-asserted-by":"crossref","unstructured":"Ay C, Dunkler D, Pirker R. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012; 97(8):1158-1164.","DOI":"10.3324\/haematol.2011.054718"},{"key":"43426","doi-asserted-by":"crossref","unstructured":"Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-1850.","DOI":"10.1056\/NEJM200012213432504"},{"key":"43427","doi-asserted-by":"crossref","unstructured":"Englisch C, Moik F, Nopp S. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv. 2022.","DOI":"10.1182\/bloodadvances.2021006283"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281315\/74852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281315\/75188","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10802\/74852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:21Z","timestamp":1794045741000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281315","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}